Literature DB >> 31519508

Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.

Jennifer Chu1, Wenhan Zhang2, Regina Cencic1, William G Devine2, Dmitri Beglov3, Thomas Henkel4, Lauren E Brown2, Sandor Vajda5, John A Porco6, Jerry Pelletier7.   

Abstract

Rocaglates share a common cyclopenta[b]benzofuran core that inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase, eIF4A. Working as interfacial inhibitors, rocaglates stabilize the association between eIF4A and RNA, which can lead to the formation of steric barriers that block initiating ribosomes. There is significant interest in the development and expansion of rocaglate derivatives, as several members of this family have been shown to possess potent anti-neoplastic activity in vitro and in vivo. To further our understanding of rocaglate diversity and drug design, herein we explore the RNA clamping activity of >200 unique rocaglate derivatives. Through this, we report on the identification and characterization of a potent class of synthetic rocaglates called amidino-rocaglates. These compounds are among the most potent rocaglates documented to date and, taken together, this work offers important information that will guide the future design of rocaglates with improved biological properties.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  amidino-rocaglates; eIF4A; eIF4F; interfacial inhibitor; translation initiation

Year:  2019        PMID: 31519508      PMCID: PMC6874763          DOI: 10.1016/j.chembiol.2019.08.008

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  27 in total

Review 1.  Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae).

Authors:  Sherif S Ebada; Neil Lajkiewicz; John A Porco; Min Li-Weber; Peter Proksch
Journal:  Prog Chem Org Nat Prod       Date:  2011

Review 2.  The Organizing Principles of Eukaryotic Ribosome Recruitment.

Authors:  Jerry Pelletier; Nahum Sonenberg
Journal:  Annu Rev Biochem       Date:  2019-06-20       Impact factor: 23.643

3.  The ATP-dependent interaction of eukaryotic initiation factors with mRNA.

Authors:  R D Abramson; T E Dever; T G Lawson; B K Ray; R E Thach; W C Merrick
Journal:  J Biol Chem       Date:  1987-03-15       Impact factor: 5.157

4.  Biomimetic photocycloaddition of 3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation.

Authors:  Stéphane P Roche; Regina Cencic; Jerry Pelletier; John A Porco
Journal:  Angew Chem Int Ed Engl       Date:  2010-09-03       Impact factor: 15.336

5.  Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors.

Authors:  Wenhan Zhang; Jennifer Chu; Andrew M Cyr; Han Yueh; Lauren E Brown; Tony T Wang; Jerry Pelletier; John A Porco
Journal:  J Am Chem Soc       Date:  2019-07-30       Impact factor: 15.419

6.  Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.

Authors:  Francis Robert; William Roman; Alexandre Bramoullé; Christof Fellmann; Anne Roulston; Chaim Shustik; John A Porco; Gordon C Shore; Michael Sebag; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

7.  A cellular response linking eIF4AI activity to eIF4AII transcription.

Authors:  Gabriela Galicia-Vázquez; Regina Cencic; Francis Robert; Aouod Quang Agenor; Jerry Pelletier
Journal:  RNA       Date:  2012-05-15       Impact factor: 4.942

8.  Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.

Authors:  Marie-Eve Bordeleau; Francis Robert; Baudouin Gerard; Lisa Lindqvist; Samuel M H Chen; Hans-Guido Wendel; Brigitte Brem; Harald Greger; Scott W Lowe; John A Porco; Jerry Pelletier
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

9.  eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Authors:  Lise Boussemart; Hélène Malka-Mahieu; Isabelle Girault; Delphine Allard; Oskar Hemmingsson; Gorana Tomasic; Marina Thomas; Christine Basmadjian; Nigel Ribeiro; Frédéric Thuaud; Christina Mateus; Emilie Routier; Nyam Kamsu-Kom; Sandrine Agoussi; Alexander M Eggermont; Laurent Désaubry; Caroline Robert; Stéphan Vagner
Journal:  Nature       Date:  2014-07-27       Impact factor: 49.962

10.  Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.

Authors:  Shintaro Iwasaki; Stephen N Floor; Nicholas T Ingolia
Journal:  Nature       Date:  2016-06-15       Impact factor: 49.962

View more
  17 in total

1.  The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy.

Authors:  Thomas E Webb; Marc Davies; John Maher; Debashis Sarker
Journal:  Clin Transl Radiat Oncol       Date:  2020-07-24

2.  Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.

Authors:  Mingming Chen; Miwako Asanuma; Mari Takahashi; Yuichi Shichino; Mari Mito; Koichi Fujiwara; Hironori Saito; Stephen N Floor; Nicholas T Ingolia; Mikiko Sodeoka; Kosuke Dodo; Takuhiro Ito; Shintaro Iwasaki
Journal:  Cell Chem Biol       Date:  2020-12-08       Impact factor: 8.116

3.  Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.

Authors:  Christopher P Mill; Warren Fiskus; Courtney D DiNardo; Christine Birdwell; John A Davis; Tapan M Kadia; Koichi Takahashi; Nicholas Short; Naval Daver; Maro Ohanian; Gautam Borthakur; Steven M Kornblau; Michael R Green; Yuan Qi; Xiaoping Su; Joseph D Khoury; Kapil N Bhalla
Journal:  Blood       Date:  2022-02-10       Impact factor: 25.476

4.  Rocaglates Induce Gain-of-Function Alterations to eIF4A and eIF4F.

Authors:  Jennifer Chu; Wenhan Zhang; Regina Cencic; Patrick B F O'Connor; Francis Robert; William G Devine; Asher Selznick; Thomas Henkel; William C Merrick; Lauren E Brown; Pavel V Baranov; John A Porco; Jerry Pelletier
Journal:  Cell Rep       Date:  2020-02-25       Impact factor: 9.423

5.  Discovery and Preliminary Characterization of Translational Modulators that Impair the Binding of eIF6 to 60S Ribosomal Subunits.

Authors:  Elisa Pesce; Annarita Miluzio; Lorenzo Turcano; Claudia Minici; Delia Cirino; Piera Calamita; Nicola Manfrini; Stefania Oliveto; Sara Ricciardi; Renata Grifantini; Massimo Degano; Alberto Bresciani; Stefano Biffo
Journal:  Cells       Date:  2020-01-10       Impact factor: 6.600

Review 6.  General and Target-Specific DExD/H RNA Helicases in Eukaryotic Translation Initiation.

Authors:  Leo Shen; Jerry Pelletier
Journal:  Int J Mol Sci       Date:  2020-06-20       Impact factor: 5.923

7.  Interactome Mapping of eIF3A in a Colon Cancer and an Immortalized Embryonic Cell Line Using Proximity-Dependent Biotin Identification.

Authors:  Diep-Khanh Vo; Alexander Engler; Darko Stoimenovski; Roland Hartig; Thilo Kaehne; Thomas Kalinski; Michael Naumann; Johannes Haybaeck; Norbert Nass
Journal:  Cancers (Basel)       Date:  2021-03-14       Impact factor: 6.639

8.  Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.

Authors:  Lee-Or Herzog; Beth Walters; Roberta Buono; J Scott Lee; Sharmila Mallya; Amos Fung; Honyin Chiu; Nancy Nguyen; Boyang Li; Anthony B Pinkerton; Michael R Jackson; Robert J Schneider; Ze'ev A Ronai; David A Fruman
Journal:  Br J Cancer       Date:  2020-12-14       Impact factor: 7.640

Review 9.  Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.

Authors:  Yuki Nishida; Ran Zhao; Lauren E Heese; Hiroki Akiyama; Shreya Patel; Alex M Jaeger; Rodrigo O Jacamo; Kensuke Kojima; Man Chun John Ma; Vivian R Ruvolo; Dhruv Chachad; William Devine; Susan Lindquist; R Eric Davis; John A Porco; Luke Whitesell; Michael Andreeff; Jo Ishizawa
Journal:  Leukemia       Date:  2021-06-14       Impact factor: 12.883

10.  Translation Inhibition by Rocaglates Activates a Species-Specific Cell Death Program in the Emerging Fungal Pathogen Candida auris.

Authors:  Kali R Iyer; Luke Whitesell; John A Porco; Thomas Henkel; Lauren E Brown; Nicole Robbins; Leah E Cowen
Journal:  mBio       Date:  2020-03-10       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.